Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia… (NCT06535542) | Clinical Trial Compass
RecruitingNot Applicable
Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in Emiratis
United Arab Emirates40 participantsStarted 2024-07-29
Plain-language summary
This pilot study investigates integrating whole genome sequencing and digital twin technology for managing hypercholesterolemia in Abu Dhabi clinics. It aims to establish protocols for larger future studies and incorporate genomic insights into routine medical care.
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with 2 or more LDL-C levels greater than 190 mg/dL or 5.0 mmol/L in the past 12 months
* Undiagnosed patients meeting Possible, Probable or Definitive FH criteria according to Dutch Lipid Clinic Network (DLCN) criteria (Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093/eurheartj/ehr158. Epub 2011 Jun 28.)
* Patients who have not been on anti-lipidemic medication in the past 3 months
* Ages 18-55
* Emirati national
* All patients must be fluent in English or Arabic
Exclusion Criteria:
* \- Patients who do not meet the above criteria
* Patients with a previous diagnosis of FH
* Patients with a progressive debilitating illness
* Patient with untreated hypothyroidism, history of proteinuria, obstructive liver disease, chronic renal failure, human immunodeficiency virus infection, or on immunosuppressant or steroid or psychiatric medications
* Patients with untreated clinical anxiety or depression (as measured by a Hospital Anxiety and Depression Scale (HADS) score of ≥ 16 on the depression subscale)
* Patients who are pregnant
What they're measuring
1
Diagnostic capabilities
Timeframe: From consent date until first documented report, up to 6 months